Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Aclidinium inhaler (Eklira Genuair) | For COPD only | |
 | Aerobika® oscillating positive expiratory pressure (OPEP) device | Review use after 6 months. | |
| Aminophylline injection (Phyllocontin Continus®) | Hospital use only | |
| Aminophylline (Phyllocontin Continus®) | ||
| Anoro® Ellipta® 55/22mcg (multi dose dry powder inhaler device) | To be used in line with COPD guidance | |
 | Bambuterol tablets | Specialist initiation for severe brittle asthma / CF | |
| Benralizumab | ||
| Duaklir Genuair | Aclidinium bromide + formoterol fumarate (Fixed Dose Combination). To be used in in-line with COPD Guidance. | |
| Formoterol | ||
| Glycopyrronium inhaler | For COPD only | |
| Haleraid® | ||
| Ipratropium inhaler | ||
| Ipratropium nebulised | ||
| Kaftrio® | NHSE commissioned | |
| Lumacaftor-ivacaftor (Orkambi®) | ||
| Mepolizumab (Nucala®) | ||
| Peak flow meter | ||
| Salbutamol inhaler | ||
| Salbutamol injection | ||
| Salbutamol nebulised | ||
| Salbutamol oral | ||
| Salmeterol inhaler | Prescribe by brand to ensure patients receive the device they are used to. Check licensed indication (differences among brands). Be aware of differences in excipients among the different brands- APC listing of current formulary brands | |
| Sodium chloride (Bebuliser diluent) | ||
| Spacer device | Able Spacer® - For use with all pressurised (aerosol) inhalers | |
| Terbutaline inhaler | ||
| Terbutaline nebulised | As an alternative to salbutamol nebules if salbutamol is in short supply | |
| Tezacaftor and ivacaftor (Symkevi®) | ||
| Tezepelumab | ||
| Theophylline (Uniphyllin continus) | Please refer to the current British National Formulary for advice on monitoring plasma-theophylline level. Theophylline levels may rise when patient stops smoking. | |
| Tiotropium | Prescribe by brand to ensure patients receive the device they are used to. Check licensed indication (differences among brands). Be aware of differences in excipients among the different brands - APC listing of current formulary brands | |
| Tiotropium and Olodaterol (Spiolto® Respimat®) | For COPD | |
| Ultibro breezhaler | Indacaterol maleate and glycopyrronium bromidfe. To be used in line with COPD guidance | |
| Umeclidinium bromide (Incruse Ellipta®) | To be used in line with COPD guidance |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
